Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase[...]
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
02/29/2024 | News release | Distributed by Public on 02/29/2024 07:38
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact